Advertisement

Therapie — Nichtglykosidische positiv-inotrope Substanzen

  • G. Richardt
  • A. Schömig
Part of the Aktuelle Therapieprinzipien in Kardiologie und Angiologie book series (THERAPIEPRINZ.)

Zusammenfassung

In der Vorstellung, daß die Reduktion der myokardialen Kontraktionskraft das Hauptproblem der Herzinsuffizienz ist, wurden verschiedene positiv-inotrope Pharmaka zur intravenösen und oralen Therapie der Herzinsuffizienz entwickelt. Auf der Suche nach positiv-inotropen Substanzen hat man sich daran orientiert, daß die Stimulation kardialer β1 Rezeptoren die Kontraktilität des Myokards steigert und daß diese Wirkung intrazellulär durch „second messenger“ wie zyklisches Adenosinmonophosphat (cAMP) und Kalzium vermittelt wird. Mittlerweile sind Substanzen verfügbar, die durch β-Stimulation, Hemmung des cAMP-Abbaus oder Steigerung der Kalziumempfindlichkeit positiv-inotrope Wirkungen hervorrufen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Applefeld MM, Newman KA, Grove WR, Sutton FJ, Roffman DS, Reed WP, Linberg SE (1983) Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure. Am J Cardiol 51:455–458PubMedCrossRefGoogle Scholar
  2. Awan NA, Needham KE, Evenson MK, Mason DT (1981) Comparison of hemodynamic actions of pirbuterol and dobutamine on cardiac function in severe congestive heart failure. Am J Cardiol 47:665–669PubMedCrossRefGoogle Scholar
  3. Bendersky R, Chatterjee K, Parmley WW, Brundage BH, Ports TA (1981) Dobutamine in chronic ischemic heart failure: Alterations in left ventricular function and coronary hemodynamics. Am J Cardiol 48:554–558PubMedCrossRefGoogle Scholar
  4. Benotti JR, Grossman W, Braunwald E, Carabello BA (1980) Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circulation 62:28–34PubMedGoogle Scholar
  5. Benotti JR, Grossman W, Braunwald E, Davolos DD, Alousi AA (1978) Hemodynamic assessment of amrinone. N Engl J Med 299:1373–1377PubMedCrossRefGoogle Scholar
  6. Beregovich J, Bianchi C, D Angelo R, Diaz R, Rubier S (1975) Haemodynamic effects of a new inotropic agent (dobutamine) in chronic cardiac failure. Br Heart J 37:629–634PubMedCrossRefGoogle Scholar
  7. Cohn JN (1989) Inotropic therapy for heart failure. N Engl J Med 320:729–731PubMedCrossRefGoogle Scholar
  8. Colucci WS, Alexander RW, Williams GH et al. (1981) Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med 305:185–190PubMedCrossRefGoogle Scholar
  9. Colucci WS, Wright RF, Braunwald E (1986) New positive inotropic agents in the treatment of congestive heart failure. N Engl J Med 314:349–358PubMedCrossRefGoogle Scholar
  10. David D, Zaks JM (1986) Arrhythmias associated with intermittent outpatient dobutamine infusion. Angiology 37:86–91PubMedCrossRefGoogle Scholar
  11. Dei Cas L, Barilli AC, Metra M et al. (1986) Multicenter study on the clinical efficacy of chronic ibopamine administration. Arzneimittelforsch 36:383–385Google Scholar
  12. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R (1989) A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 320:677–683PubMedCrossRefGoogle Scholar
  13. German and Austrian Xamoterol Study Group (1988) Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet 489–493Google Scholar
  14. Gillespie TA, Ambos HD, Sobel BE, Roberts R (1977) Effects of dobutamine in patients with acute myocardial infarction. Am J Cardiol 39:584–588CrossRefGoogle Scholar
  15. Goldberg LI (1974) Dopamine — Clinical uses of an endogenous catecholamine. N Engl J Med 291:707–710PubMedCrossRefGoogle Scholar
  16. Goldberg LI, Rajfer SI (1985) Dopamine receptors: applications in clinical cardiology. Circulation 72:245–248PubMedCrossRefGoogle Scholar
  17. Hodgson SM, Aja M, Soulzin RP (1984) Intermittend ambulatory dobutamine infusions for patients awaiting cardiac transplantation. Am J Cardiol 53:775CrossRefGoogle Scholar
  18. Katz AM (1990) Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. N Engl J Med 332:100–110Google Scholar
  19. Leier CV, Webel J, Bush CA (1977) The cardiovascular effects of the continous infusion of dobutamine in patients with severe cardiac failure. Circulation 56:468–472PubMedGoogle Scholar
  20. Leier CV, Heban PT, Huss P, Bush CA, Lewis RP (1978) Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 58:466–475PubMedGoogle Scholar
  21. LeJemtel TH, Sonnenblick EH (1984) Should the failing heart be stimulated? N Engl J Med 310:1384–1385PubMedCrossRefGoogle Scholar
  22. Loeb HS, Bredakis J, Gunnar RM (1977) Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure. Circulation 55:375–381PubMedGoogle Scholar
  23. Maskin C, Forman R, Klein A, Sonnenblick EH, LeJemtel TH (1982) Long-term amrinone therapy in patients with severe heart failure. Am J Med 72:113–118PubMedCrossRefGoogle Scholar
  24. Massie B, Bourassa M, DiBianco R, Hess M, Konstam M, Likoff M, Packer M (1985) Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial. Circulation 71:963–975PubMedCrossRefGoogle Scholar
  25. McDonald RH Jr, Goldberg LI, McNay JL (1964) Effects of dopamine in man: Augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J Clin Invest 43:1116–1124PubMedCrossRefGoogle Scholar
  26. Olson EM, Kim D, Smith TW, Marsh JD (1987) Mechanism of the positive inotropic effect of milrinone in cultured embryonic chick ventricular cells. J Mol Cell Cardiol 19:95–104PubMedCrossRefGoogle Scholar
  27. Packer M (1990) Pathophysiological mechanism underlying the effects of ß-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure. Circulation [Suppl I] 82:77–88Google Scholar
  28. Packer M, Canner JR, Rodehoffen RG et al. (1991) Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325:1468–1475PubMedCrossRefGoogle Scholar
  29. Packer M, Medina N, Yushak M (1984) Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation 70:1038–1047PubMedCrossRefGoogle Scholar
  30. Pozen RG, DiBianco R, Katz RJ, Bortz R, Myerburg RJ, Fletcher RD (1981) Myocardial metabolic and hemodynamic effects of dobutamine in heart failure complicating coronary artery disease. Circulation 63:1279–1285PubMedCrossRefGoogle Scholar
  31. Rajfer SI, Davis FR (1990) Role of dopamine receptors and the utility of dopamine agonists in heart failure. Circulation [Suppl I] 82:97–102Google Scholar
  32. Rude RE, Turi Z, Brown EJ et al. (1981) Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure. Circulation 64:139–145PubMedCrossRefGoogle Scholar
  33. Sannia L, Ibba V, Castellaccio M, Dore L (1986) Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure. Arzneimittelforsch 36:355–359PubMedGoogle Scholar
  34. Sharma B, Goodwin JF (1978) Beneficial effect of salbutamol on cardiac function in severe congestive cardiomyopathy. Circulation 58:449–460PubMedGoogle Scholar
  35. Siegel LA, LeJemtel TH, Strom J et al. (1983) Improvement in exercise capacity despite cardiac deterioration: Noninvasive assessment of long-term therapy with amrinone in severe heart failure. Am Heart J 106:1042–1047PubMedCrossRefGoogle Scholar
  36. Silver PJ (1989) Biochemical aspects of inhibition of cardiovascular low (Km) cyclic adenosine monophosphate phosphodiesterase. Am J Cardiol 63:2A-8APubMedCrossRefGoogle Scholar
  37. Sonnenblick EH, Frishman WH, Lejemtel TH (1979) Dobutamine: A new synthetic cardioactive sympathetic amine. N Engl J Med 300:17–22PubMedCrossRefGoogle Scholar
  38. Stoner JD, Bolen JL, Harrison DC (1977) Comparison of dobutamine and dopamine in treatment of severe heart failure. Br Heart J 39:536–539PubMedCrossRefGoogle Scholar
  39. Timmis AD, Smyth P, Jewitt DE (1985) Milrinone in heart failure. Br Heart J 54:42–47PubMedCrossRefGoogle Scholar
  40. Toda N, Goldberg LI (1975) Effects of dopamine on isolated canine coronary arteries. Cardiovasc Res 9:384–389PubMedCrossRefGoogle Scholar
  41. Tuttle RR, Hillmann CC, Toomey RE (1976) Differential β-adrenergic sensitivity of atrial and ventricular tissue assessed by chronotropic, inotropic, and cyclic AMP responses to isoprenaline and dobutamine. Cardiovasc Res 10:452–458PubMedCrossRefGoogle Scholar
  42. Tuttle RR, Mills J (1975) Dobutamine. Circ Res 36:185–196Google Scholar
  43. Unverferth DV, Magorien RD, Lewis RP, Leier CV (1980) Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 100:622–630PubMedCrossRefGoogle Scholar
  44. Unverferth DV, Magorien RD, Altschuld R, Kolibash AJ, Lewis RP, Leier CV (1983) The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J 106:29–34PubMedCrossRefGoogle Scholar
  45. Vatner SF, McRitchie RJ, Braunwald E (1974) Effects of dobutamine on left ventricular performance, coronary dynamics, and distribution of cardiac output in conscious dogs. J Clin Invest 53:1265–1273PubMedCrossRefGoogle Scholar
  46. Wahr DW, Swedberg K, Rabbino M, Hoyle MJ, Curran D, Parmley WW, Chatterjee K (1984) Intravenous and oral prenalterol in congestive heart failure. Am J Med 76:999–1005PubMedCrossRefGoogle Scholar
  47. Williams RS, Bishop T (1981) Selectivity of dobutamine for adrenergic receptor subtypes. J Clin Invest 67:1703–1711PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • G. Richardt
  • A. Schömig

There are no affiliations available

Personalised recommendations